0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correction |

Remissions in Maternal Depression and Child Psychopathology: A STAR*D-Child Report—Correction FREE

JAMA. 2006;296(10):1234. doi:10.1001/jama.296.10.1234.
Text Size: A A A
Published online

Incomplete Financial Disclosure: In the Original Contribution entitled “Remissions in Maternal Depression and Child Psychopathology: A STAR*D-Child Report” published in the March 22/29, 2006, issue of JAMA (2006;295:1389-1398), financial disclosures were omitted. The amended disclosure statement follows: Dr Weissman reported having received grant support from Eli Lilly and GlaxoSmithKline and having served as a scientific advisor to Eli Lilly. Dr Alpert reported having received research support from Aspect Medical Systems, Eli Lilly, Forest Pharmaceuticals, and Pfizer; having received research support and honoraria from Organon Inc; and having received research support from and having served as a consultant for Pharmavite LLC and Pamlab LLC. Dr Fava reported having received research support from Abbott Laboratories, Lichtwer Pharma GmbH, Lorex Pharmaceuticals; having received honoraria from EPIX Pharmaceuticals, Bayer AG, Compellis, Cypress Pharmaceuticals, Janssen Pharmaceutica, Knoll Pharmaceutical, Lundbeck, Dov Pharmaceuticals, Biovail Pharmaceuticals, BrainCells Inc, Cypress Pharmaceuticals, Fabre-Kramer Pharmaceuticals, Grunenthal GmBH, MedAvante, Sepracor, and Somerset Pharmaceuticals; and having received both research support and honoraria from Aspect Medical Systems, Astra-Zeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Novartis, Organon, Pamlab, Pharmavite, Pfizer, Roche, Sanofi/Synthelabo, Solvay Pharmaceuticals, and Wyeth-Ayerst Laboratories. Dr Trivedi reported having provided scientific consultation for or having served on the advisory boards of Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Pharmaceuticals, Johnson & Johnson, Pfizer, Sepracor, and Wyeth-Ayerst Laboratories; having served on the speaker bureaus for Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Pharmaceuticals, and Wyeth-Ayerst Laboratories; and having received researchsupport from Bristol-Myers Squibb, Cephalon, Corcept Therapeutics, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutica, National Institute of Mental Health, National Alliance for Research in Schizophrenia and Depression, Pfizer, Predix Pharmaceuticals, and Wyeth-Ayerst Laboratories. Dr Rush reported having provided scientific consultation to or served on advisory boards of Advanced Neuronetic Systems, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Health Technology Systems, Merck, Neuronetics, Ono Pharmaceuticals, Organon Pharmaceuticals, Pfizer, the Urban Institute, and Wyeth-Ayerst Laboratories; having received royalties from Guilford Press and Health Technology Systems and research and grant support from the Robert Wood Johnson Foundation, the National Institute of Mental Health, and the Stanley Foundation; having served on the speaker bureaus of Cyberonics, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, and Merck; and owning stock in Pfizer.

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.